13D Filing: Great Point Partners and Bovie Medical Corp (BVX)

¹
Consists of (i) 2,680,000 shares of Common Stock owned collectively by Biomedical Value Fund, LP (“BMVF”), Biomedical
Offshore Value Fund, Ltd. (“BOVF”), Biomedical Institutional Value Fund, LP (“BIVF”), Class D Series of
GEF-PS, LP (“GEF-PS”) and WS Investments II, LLC (“WS”), and (ii) 39,266 shares issuable upon conversion
of Series A 6% preferred stock collectively owned by each of BMVF, BOVF, BIVF, GEF-PS, and WS. Does not include: (i) Series A 6%
preferred stock convertible into 3,912,012 shares, collectively owned by each of BMVF, BOVF, BIVF, GEF-PS, and WS. The provisions
of such preferred stock restrict the conversion of such preferred stock to the extent that, after giving effect to such conversion,
the holder of the preferred stock and its affiliates and any other person or entities with which such holder would constitute
a group would beneficially own in excess of 9.985% of the number of shares of Common Stock of the Issuer outstanding immediately
after giving effect to such conversion or exercise (the “Ownership Cap”). Therefore, the reporting persons could be
deemed to beneficially own such number of shares underlying such preferred stock as would result in total beneficial ownership
by such reporting persons up to the Ownership Cap.

²
Based on a total of 27,194,251 shares outstanding, as reported by the Issuer on a Form 10-Q filed with the SEC on November 5,
2015.